Health Decisions Celebrates National Women’s Health Week with Diverse Program
Women’s Health Specialty CRO Focuses the Week on Women’s Unmet Medical Needs and Key Clinical Development Issues
Durham, North Carolina. Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies and a leader in women’s health and diagnostics studies, today announced a series of activities in observance of 2018 National Women’s Health Week. Activities include offering a complimentary webinar for developers of new treatments for heavy menstrual bleeding (HMB), providing an update on women’s unmet medical needs in three key areas, and announcing leadership of a session at the 2018 Drug Industry Association Global Annual Meeting on a critical issue in the clinical development of women’s health products – incorporating stakeholder input in protocol design.
“National Women’s Health Week is an important annual event for Health Decisions as a CRO specializing in women’s health,” stated Health Decisions’ Chief Executive Officer Patrick Phillips, BSc (Hons), D.Phil. “We are celebrating this special week with a variety of activities and announcements highlighting key issues in the development of products to improve healthcare outcomes across the female lifespan. Like our sponsorship of the walk for women at the 2018 Annual Meeting of the American College of Obstetricians and Gynecologists two weeks ago, these activities reflect the breadth and depth of our organizational commitment to improving healthcare outcomes for women.”
Health Decisions’ Chief Medical Officer, Andrea S. Lukes, MD, MHSc, FACOG, said, “Health Decisions’ activities for National Women’s Health Week 2018 include a webinar on the development of treatments in an area of unmet medical need, heavy menstrual bleeding. In addition, we are providing an update on the development landscape in three key areas of women’s health – noninvasive diagnostics, osteoporosis and female sexual dysfunction. Finally, we are announcing our leadership of a session at DIA 2018 on incorporating stakeholder input in protocol development, which we consider essential for conducting successful clinical trials in women’s health.”
“We are delighted to have Health Decisions and other companies and organizations providing such vigorous support for National Women’s Health Week,” stated Gaylyn Henderson, MPH, Public Health Advisor/Regional Women’s Health Coordinator (Acting), US-Department of Health and Human Services, Office of the Assistant Secretary for Health – Region IV. “Together we can make a real difference in women’s lives.”
Summary of Health Decisions Activities in National Women’s Health Week 2018
Health Decisions activities during National Women’s Health Week 2018 include the following:
- The webinar, “Heavy Menstrual Bleeding: Medical Background and PI and Patient Perspectives on Clinical Trials,” is now available for viewing. Dr. Lukes, an authority on heavy menstrual bleeding and clinical development of related products, led the webinar and was joined by a patient who participated in an HMB clinical trial.
- The update on women’s key unmet medical needs provides a concise overview of the development landscape in three important areas in women’s health: noninvasive diagnostics for indications including endometriosis, which affects women of reproductive age and currently requires a surgical procedure to confirm the diagnosis; new treatments for osteoporosis, which compromises the health and quality of life of many postmenopausal women, in part because many women’s adherence to current treatment regimens is limited; and improved therapeutics for female sexual dysfunction, an area with few treatment options by comparison with male sexual issues like erectile dysfunction.
- The June 25 session at the DIA Global Annual Meeting in Boston is entitled, “From Patients and Advocacy Groups to Operations and Beyond: Obtaining and Incorporating Input from Stakeholders in Protocol Design.” Dr. Lukes will lead the session, which will include presentations by Michelle Witkop, DrSc, Head of Research at the National Hemophilia Foundation, and Clint Dart, MS, Health Decisions Senior Director of Biostatistics and Programming.
Health Decisions also held a luncheon for all staff at its corporate headquarters in Durham, NC, to mark National Women’s Health Week and emphasize the importance of the company’s and each staff member’s role in the development of new products that improve healthcare outcomes for women.
About Health Decisions
Health Decisions is a full-service CRO offering therapeutic, operational and regulatory excellence for clinical development of drugs, diagnostics, medical devices and combination drug/devices in all areas of women’s health. Based on therapeutic and operational experience and investigator relationships developed in studies conducted over the past 28 years, Health Decisions successfully addresses the challenges of developing diagnostics in all therapeutic areas and drugs and devices in areas including reproductive and sexual health, menopause, pain management, osteoporosis/osteoarthritis, reproductive psychiatry, gynecologic oncology and general gynecology indications. Health Decisions is headquartered in Durham, NC.
# # #
+1 919.967.1111 ext. 520
lhammill @ healthdec.com